Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XPF-001 crossover study in inherited erythromelalgia
NL-OMON34941Phase 2Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of funapide in erythromelalgia (2 arms), sponsored by Xenon Pharmaceuticals. Primary endpoints: Pain intensity numeric rating scale, Categorical rating scale and 6 more. Started Mar 2010; status: active, not recruiting.
02
Drugs
funapide
03
Conditions
erythromelalgia
Beyond the preview
Go deeper on NL-OMON34941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34941.